Silence Therapeutics plc
SLNNASDAQHealthcare● Active
$6.13
$-0.04(-0.65%)
Market Cap$289544101
P/E Ratio—
52W High$8.4
52W Low$4.19
Silence Therapeutics plc (SLN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SLN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.32
Est. -$0.33 · +3.0%
Revenue
$0.00B
Est. $0.00B · -66.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
SLN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.00B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.14 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.33 | -$0.32 | +3.0% | $0.00B | $0.00B | -66.4% |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.32 | -$0.25 | +21.9% | $0.00B | $0.00B | -98.7% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.40 | -$0.45 | -12.5% | $0.00B | $0.00B | -94.9% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.27 | -$0.54 | -100.0% | $0.00B | $0.00B | -93.1% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.18 | -$0.60 | -233.3% | $0.00B | $0.00B | -93.9% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.45 | $0.27 | +160.0% | $0.02B | $0.01B | +259.4% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.42 | -$0.75 | -78.6% | $0.00B | $0.01B | -79.9% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.14
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.32
EPS Est.
-$0.33
EPS Surpr.
+3.0%
Revenue
$0.00B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.25
EPS Est.
-$0.32
EPS Surpr.
+21.9%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.40
EPS Surpr.
-12.5%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.54
EPS Est.
-$0.27
EPS Surpr.
-100.0%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.60
EPS Est.
-$0.18
EPS Surpr.
-233.3%
Revenue
$0.00B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.27
EPS Est.
-$0.45
EPS Surpr.
+160.0%
Revenue
$0.02B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.75
EPS Est.
-$0.42
EPS Surpr.
-78.6%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.35 | $-0.10 | $0.02 | 1 |
| Q3 FY2028 | $-0.35 | $-0.10 | $0.02 | 1 |
| Q2 FY2028 | $-0.35 | $-0.10 | $0.02 | 1 |
| Q1 FY2028 | $-0.34 | $-0.10 | $0.02 | 1 |
| Q4 FY2027 | $-0.48 | $-0.14 | $0.03 | 1 |
| Q3 FY2027 | $-0.41 | $-0.12 | $0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +3.0% | $7.36 | $6.95 | -5.57% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +21.9% | $5.78 | $5.50 | -4.84% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -12.5% | $6.24 | $6.45 | +3.37% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -100.0% | $5.32 | $5.38 | +1.13% |
| ▼ Q2 FY2025 | May 8, 2025 | -233.3% | $3.70 | $3.56 | -3.78% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +160.0% | $4.77 | $4.72 | -1.05% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -78.6% | $15.24 | $13.98 | -8.27% |
| ▲ Q2 FY2024 | May 16, 2024 | +78.3% | $22.33 | $22.94 | +2.73% |
Q2 FY2026-5.57%
Report Date
May 7, 2026
EPS Beat/Miss
+3.0%
Price Before
$7.36
Price After
$6.95
Q1 FY2026-4.84%
Report Date
Mar 5, 2026
EPS Beat/Miss
+21.9%
Price Before
$5.78
Price After
$5.50
Q4 FY2025+3.37%
Report Date
Nov 6, 2025
EPS Beat/Miss
-12.5%
Price Before
$6.24
Price After
$6.45
Q3 FY2025+1.13%
Report Date
Aug 7, 2025
EPS Beat/Miss
-100.0%
Price Before
$5.32
Price After
$5.38
Q2 FY2025-3.78%
Report Date
May 8, 2025
EPS Beat/Miss
-233.3%
Price Before
$3.70
Price After
$3.56
Q1 FY2025-1.05%
Report Date
Feb 27, 2025
EPS Beat/Miss
+160.0%
Price Before
$4.77
Price After
$4.72
Q4 FY2024-8.27%
Report Date
Nov 14, 2024
EPS Beat/Miss
-78.6%
Price Before
$15.24
Price After
$13.98
Q2 FY2024+2.73%
Report Date
May 16, 2024
EPS Beat/Miss
+78.3%
Price Before
$22.33
Price After
$22.94
Avg Beat Reaction-2.18%
Avg Miss Reaction-1.89%
Beat Rate4 / 8 quarters
Largest Move-8.27% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SLN ends December
Silence Therapeutics plc (SLN) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.32 — beating the analyst consensus of $-0.33 by +3.0%. SLN has beaten EPS estimates for 2 consecutive quarters. The next SLN earnings date is expected around September 1, 2026.
Each quarter, investors track SLN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SLN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SLN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SLN earnings · 5 questionsSilence Therapeutics plc's next earnings report is expected around September 1, 2026. SLN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SLN historically reports after market close (AMC).
SLN earnings datewhen is SLN earningsSLN next earnings datewhen does SLN report earningsSLN earnings calendar
▸ Source: FMP · Silence Therapeutics plc SEC filings · US GAAP · Silence Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026